17 results about "Sodium channel" patented technology

Small molecule inhibitors of Nav1.8 voltage-gated sodium ion channel, including compounds of formula (I), (II), (III), (IV), and (V) are described. Also described are pharmaceutical compositions containing a compound of formula (I), (II), (III), (IV), and (V) and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases and cardiovascular diseases, such as atrial fibrillation.

This invention discloses a rare-earth metal gradient-doped polyanionic cathode material, its preparation method, and its application. The molecular formula of the rare-earth metal gradient-doped polyanionic cathode material is Na. 2+2x‑y RE y Fe 2‑x (SO4)3, in the rare earth metal gradient-doped polyanionic cathode material, rare earth metal elements enter the crystal lattice of the polyanionic cathode material in the form of rare earth metal ions, and the doping content of the rare earth metal ions decreases in a gradient along the direction from the crystal lattice surface to the bulk phase. The polyanionic cathode material is an Alluaudite-type sodium iron sulfate cathode material. This invention effectively solves the kinetic mismatch problem of "fast ions but slow electrons" in rate performance by simultaneously optimizing the electronic structure and sodium ion channels through rare earth doping, significantly improving the structural stability of the material under long-cycle and fast-charge-discharge conditions. Simultaneously, the assembled sodium-ion battery exhibits excellent wide-temperature performance.

The invention provides new application of lauric acid, and researches on the inhibiting effect of lauric acid on a cardiac voltage gated sodium channel Nav1.5 and the action mode of lauric acid in electrophysiological conduction prove that natural polysaturated fatty acid lauric acid is a potential Nav1.5 sodium channel inhibitor for the first time. Electrophysiological characterization shows that lauric acid is the most effective monomer in natural polysaturated fatty acid screened for inhibiting Nav1.5, and the IC50 value is 27.40 + / -12.78 mu M.

The invention discloses a method for rapidly detecting sodium ion channel L1014F mutation of liriomyza trifoliata and a special kit, and belongs to the technical field of agricultural biology. The method comprises the following steps: extracting the DNA of the liriomyza trifoliate; carrying out PCR (Polymerase Chain Reaction) amplification by adopting two groups of primer pairs; an upstream primer of the first group of primer pair is as shown in SEQ ID NO.2, an upstream primer of the second group of primer pair is as shown in SEQ ID NO.1, and a downstream primer of the second group of primer pair is as shown in SEQ ID NO.3. Result judgment: when a 502 bp band appears in amplification of the first group of primer pairs, the L1014F site of the sample is not mutated; and when a 502 bp band appears in the amplification of the second group of primer pairs, the L1014F site of the sample is mutated. According to the method, mononucleotide variation typing can be achieved only through a conventional PCR instrument and electrophoresis, operation is easy and convenient, and the method is suitable for rapid monitoring of pyrethroid drug resistance of liriomyza trifoliate and investigation of field population resistance gene frequency.

The invention belongs to the field of medicinal chemistry. The invention discloses a heterocyclic compound as well as a preparation method and application thereof, and particularly relates to a series of blockers of sodium ion channels with novel structures as well as a preparation method and application thereof. The structure of the compound is shown as a general formula (I). The compounds or stereoisomers, racemes, geometric isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used for treating or / and preventing sodium ion channel (Nav)-mediated related diseases.

The present invention relates to the field of pharmaceutical crystal forms, and specifically relates to crystal forms of 2-(4,4-difluoroazepin-1-yl)-N-(2-sulfamoylpyridin-4-yl)quinoline-3-carboxamide and a salt thereof, a pharmaceutical composition, and a use. The crystal forms of a compound of formula (I) and a salt thereof which are obtained in the present invention have excellent physical stability and chemical stability, and compared with free base crystal form K1 of the compound of formula (I), have significantly improved solubility, hygroscopicity and bioavailability, and are more conducive to clinical applications. Also disclosed in the present invention is a use of the crystal forms of the compound of formula (I) and the salt thereof as sodium ion channel Nav1.8 inhibitors for treating a wide range of pain.

The present invention belongs to the field of pharmaceutical chemistry. Disclosed in the present invention are a heterocyclic compound, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a series of sodium ion channel blockers having new structures, and a preparation method therefor and the use thereof. The structure thereof is as shown in the following general formula (I). These compounds or a stereoisomer, racemate, geometric isomer, tautomer, prodrug, hydrate or solvate thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof can be used for treating or / and preventing related diseases mediated by a sodium ion channel (Nav).

Provided herein are compositions and methods protection against QTc prolongation. In some embodiments, the compositions and methods comprise administering a compound having one or more of early sodium ion channel blocking, lates sodium ion channel blocking, and L-type calcium channel blocking activity. In some embodiments, the compound is sulcardine or a pharmaceutically acceptable salt thereof, such as sulcardine sulfate or sulcardine mono-edisylate.

The invention discloses an application of a sebastites verrucosa venom protein neoVTX. The invention finds that the sebastes verrucosa venom protein neoVTX has the functions of inhibiting a voltage-gated sodium ion channel and mediating muscle paralysis, can inhibit activities of zebra fish and grass goldfish, and can be used as a macromolecular probe template for exploring the voltage-gated sodium ion channel and explaining clinical symptoms of stab wounds of sebastes verrucosa; the compound can be further used for developing a medicine for paralyzing muscles and a medicine for relieving stabbing poisoning of sebastes verrucosa.

The invention discloses a compound shown in a general formula (I) or a general formula (II), a stereoisomer, a tautomer, a deuterated derivative or a pharmaceutically acceptable salt thereof, a preparation method and application of the compound, and a pharmaceutical composition containing the compound, the stereoisomer, the tautomer, the deuterated derivative or the pharmaceutically acceptable salt thereof, the compound can be used as a sodion channel subtype Nav1.8 inhibitor, and can be used as a medicine for treating and preventing pain-related diseases.

The invention relates to the field of medicine crystal forms, in particular to crystal forms of 2-(4, 4-difluoroaza-1-yl)-N-(2-sulfamoyl pyridine-4-yl) quinoline-3-formamide and salt thereof, a medicine composition and application. The obtained crystal form of the compound shown in the formula (I) and the salt thereof has excellent physical stability and chemical stability, and compared with a free alkali crystal form K1 of the compound shown in the formula (I), the crystal form of the compound shown in the formula (I) and the salt thereof has obviously improved solubility and hygroscopicity and obviously improved bioavailability, and is more beneficial to clinical application. The invention further discloses the effect of the compound shown in the formula (I) and the crystal form of the salt of the compound as an inhibitor of a sodium ion channel Nav1.8, and the compound and the salt are used for treating wide pain.

The invention provides a multiphase composite iron-based polyanion sodium ion battery positive electrode material and a preparation method thereof, a planetary ball milling reinforced phase sintering method is adopted to regulate and control an initial raw material Na / Fe feeding ratio and F element loss in a high-temperature sintering process, and a series of multiphase materials with non-stoichiometric ratios are synthesized. Wherein the material with the optimal performance is a three-phase composite material of Na7Fe7 (PO4) 6F3, Na2FePO4F and Na2Fe3 (PO4) 3, and primary particles of the material have a heterojunction structure. Excellent sodium ion channels of Na2FePO4F and Na2Fe3 (PO4) 3 in the three phases are beneficial for the Na7Fe7 (PO4) 6F3 material to release high theoretical specific capacity, and the overall actual specific capacity of the material is improved; the low-strain stable lattice structure of the Na7Fe7 (PO4) 6F3 material can slow down the Na2FePO4F lattice strain, inhibit the phase change and maintain the structural integrity of the composite material in the long cycle process, so that the material has high capacity and excellent cycle performance.

The invention discloses a method and a special kit for rapidly detecting sodium ion channel K1774N mutation of methrips vigna, and belongs to the technical field of biological detection. The method mainly comprises the following steps: 1) extracting DNA (Deoxyribose Nucleic Acid) of the cowpea 2) carrying out PCR amplification by adopting two groups of primer pairs; (3) result judgment: when a 269bp band appears in amplification of the first group of primer pairs, the detected sodion channel gene mutation site K1774N of the cowpea megthrips spp sample is not mutated; when a 269bp band appears in amplification of the second group of primer pairs, the detected sodion channel gene mutation site K1774N of the cowpea megaluthrips spp sample is mutated, and when no band appears, the detected cowpea megaluthrips spp sample is not mutated. According to the application, the mutation condition of the field cowpea megthrip K1774N mutation site can be quickly and effectively detected, and the real-time state of pyrethroid resistance of the field cowpea megthrip is effectively detected.

The invention belongs to the field of medicines, and relates to a benzenesulfonamide compound as well as a preparation method and application thereof. The invention discloses a benzenesulfonamide compound as shown in a general formula (I) and a preparation method and application thereof. The series of compounds provided by the invention can be used as lead compounds of sodium ion channel inhibitors, and are expected to be used for preparing medicines for treating arrhythmia, including premature beat, acute and recurrent atrial fibrillation, heart failure, supraventricular tachyarrhythmia (PVC), ventricular premature contraction (PVC), ventricular tachycardia (VT) or ventricular fibrillation (VF).

The application belongs to the technical field of polypeptide and medicine synthesis, and particularly relates to a cyclic peptide or salt thereof inhibiting Na V 1.8 activity and application thereof in analgesia. After a series of linear peptides composed of tryptophan, lysine and arginine are obtained, the amino acids at the head and tail are cyclized by an amide bond to obtain the cyclic peptide. The cyclic peptide or salt thereof can inhibit the current of voltage-gated sodium ion channel of mammals V 1.8, and can be developed as a Na V 1.8 inhibitor. The cyclic peptide or salt thereof can act on the Na V 1.8 receptor of mammals, and can block the transmission of pain signal for a long time. The cyclic peptide or salt thereof can enhance the resistance to pain, can be developed as a potential analgesic, and is applied to relieve pain of human and other animals, and is a Na V 1.8 ion channel related disease research and a lead drug molecule for developing a drug for treating Na V 1.8 ion channel related diseases.

The invention discloses a preparation method of a yttrium-doped sodium vanadium phosphate sodium storage positive electrode material with high capacity, which comprises the following steps: dissolving vanadium pentoxide and ascorbic acid in deionized water according to a predetermined proportion, and fully stirring to obtain a first solution; adding a predetermined mass of yttrium nitrate into the first solution, and stirring and fully dissolving to obtain a second solution; adding sodium dihydrogen phosphate and sodium carbonate with preset mass into the second solution, and stirring and fully dissolving to obtain a third solution; transferring the third solution into a reaction kettle for hydrothermal reaction, and drying after the reaction is finished to obtain a precursor I; grinding the precursor I, and preheating in an argon / hydrogen mixed atmosphere to obtain a precursor II; and continuously grinding the precursor II, and carrying out heat treatment in an argon / hydrogen mixed atmosphere to obtain a final product. According to the invention, the problem of poor cycle performance caused by poor conductivity and large sodium intercalation volume change of the sodium vanadium phosphate positive electrode material is solved, and a sodium ion channel is widened and the structural stability is enhanced through yttrium ion doping.

Provided herein are compositions and methods protection against QTc prolongation. In some embodiments, the compositions and methods comprise administering a compound having one or more of early sodium ion channel blocking, lates sodium ion channel blocking, and L-type calcium channel blocking activity. In some embodiments, the compound is sulcardine or a pharmaceutically acceptable salt thereof, such as sulcardine sulfate or sulcardine mono-edisylate.